P&G Wins Dismissal of Dental Floss PFAS Lawsuit

/in ,

A federal court has dismissed a proposed class action alleging that Procter & Gamble misled consumers about the health and environmental qualities of its dental floss due to the alleged presence of PFAS, holding that the plaintiff failed to establish standing.

The suit relied on test results allegedly showing that Oral-B Glide products contain 302,400 ppm of organic fluorine.  The suit also cited results from a separate laboratory that allegedly detected specific PFAS—including four not disclosed by the company, which publicly acknowledges that some Oral-B products contain the chemical PTFE.

In an order issued January 9, 2026, the Southern District of New York concluded that significant gaps in the testing allegations prevented the plaintiff from establishing standing under a price-premium theory of injury.

“Plaintiff does not clarify, among other things, whether the samples tested were taken from products Plaintiff actually purchased; when the samples were collected; how many samples were collected and tested for each product line; or whether all tested samples yielded positive results for PFAS,” the opinion reads.

These deficiencies, as well as insufficient information about whether the test samples were acquired at the same time or within geographic proximity to the purchased products, would also doom arguments that the entire product line was contaminated, the court added.

The plaintiff’s benefit-of-bargain theory fared no better.  The court found no concrete and particularized injury, citing the vague test results, the lack of alleged physical harm, and the plaintiff’s failure to identify a less expensive, PFAS-free dental floss product necessary to support the notion of a premium.

The decision aligns with a growing body of case law dismissing cases challenging marketing claims based on the alleged presence of PFAS for lack of standing, including a recent dismissal involving similar allegations against Coca-Cola, a decision the court cited repeatedly.

The case is Dalewitz v. The Procter & Gamble Co., No. 22-cv-7323 (S.D.N.Y.).  The plaintiff has until February 10, 2026, to file an amended complaint.